Primrose Bio
PrivateLast Round
Growth Equity
Sep 22, 2026
Est. Valuation
$30.06M
Total Funding Raised
$34.58M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Primrose Bio is a biotechnology company that provides an integrated technology platform for solving complex drug manufacturing and design challenges for protein and nucleic acid medicines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Primrose Bio Comparables
Compare Primrose Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ExPLoRNA Therapeutics | 79% | |
| Maravai Lifesciences Holdings, Inc. | 77% | |
| CELLSCRIPT, LLC | 76% |
Primrose Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Sep 22, 2026 | ||||
| Series B | Jun 17, 2024 | ||||
| Series A | Sep 18, 2023 | ||||
| Grant | Apr 26, 2023 | ||||
| Grant | Apr 15, 2020 | ||||
Grant | Sep 17, 2018 |
Key People
Founding team and executive leadership
Primrose Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ligand Pharmaceuticals | Growth Equity, Series A |
| Agent Capital | Growth Equity |
| NIH RADx | Grant |
| Signet Healthcare Partners | Growth Equity |
| LDV Partners | Growth Equity |
| National Institute of General Medical Sciences | Grant |
| 1315 Capital | Growth Equity, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2026
Signet Healthcare Partners led the round with participation from Agent Capital and LDV Partners.
- Nov 10, 2025
Launched Prima RNApols ExTend Cap AU for mRNA manufacturing.
Primrose Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Primrose Bio's valuation, stock price, and market status.
Is Primrose Bio a public or private company?
Primrose Bio is a private company.
What is the current stock price of Primrose Bio?
Primrose Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Primrose Bio worth (valuation)?
Primrose Bio's valuation is estimated at $30.1M based on funding round data.
Can I buy Primrose Bio stock?
Primrose Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Primrose Bio's last funding round?
Primrose Bio's most recent funding round was VC Round on September 18, 2023.
Who are the main investors in Primrose Bio?
Key investors in Primrose Bio include Ligand Pharmaceuticals, 1315 Capital.
Will Primrose Bio IPO soon?
No public IPO plans have been announced for Primrose Bio.
How can I track Primrose Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Primrose Bio's secondary market activity and sign up for updates.